Core Insights - Medtronic reported $9.02 billion in revenue for the quarter ended January 2026, marking an 8.7% year-over-year increase and a surprise of +1.35% over the Zacks Consensus Estimate of $8.9 billion [1] - The earnings per share (EPS) for the same period was $1.36, slightly down from $1.39 a year ago, with an EPS surprise of +2.07% compared to the consensus estimate of $1.33 [1] Revenue Breakdown - U.S. Revenue: $4.49 billion, a 6% year-over-year increase, but below the average estimate of $4.59 billion [4] - International Revenue: $4.52 billion, exceeding the average estimate of $4.3 billion [4] - Cardiovascular Revenue: $3.46 billion, a 13.8% year-over-year increase, surpassing the average estimate of $3.39 billion [4] - Neuroscience Revenue: $2.56 billion, a 4.1% year-over-year increase, slightly below the average estimate of $2.58 billion [4] - Medical Surgical Revenue: $2.17 billion, a 4.9% year-over-year increase, exceeding the average estimate of $2.14 billion [4] - Diabetes Revenue: $796 million, a 14.7% year-over-year increase, surpassing the average estimate of $773.73 million [4] - Cardiac Rhythm & Heart Failure Revenue: $1.86 billion, a significant 20.1% year-over-year increase, exceeding the average estimate of $1.8 billion [4] Stock Performance - Medtronic shares have returned +2.8% over the past month, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - Labcorp Holdings reported revenue of $3.52 billion for the quarter ended December 2025, reflecting a 5.6% increase year-over-year [1] - The company's EPS for the quarter was $4.07, up from $3.45 in the same quarter last year, with an EPS surprise of +2.98% compared to the consensus estimate of $3.95 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $3.55 billion, resulting in a revenue surprise of -0.97% [1] Group 2 - Key metrics indicate that Labcorp's shares have returned +4.3% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Group 3 - The net book-to-bill ratio for Labcorp was reported at 1.1%, matching the average estimate based on two analysts [4] - Revenues from Biopharma Laboratory Services were $793 million, slightly above the average estimate of $791.05 million, representing a year-over-year change of +3.4% [4] - Revenues from Diagnostics Laboratories were $2.73 billion, below the average estimate of $2.77 billion, with a year-over-year change of +5.5% [4] - Adjusted Operating Income for Diagnostics Laboratories was $419.2 million, slightly below the average estimate of $423.58 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $136.1 million, exceeding the average estimate of $130.1 million [4] - Unallocated corporate expenses were reported at -$67.6 million, better than the average estimate of -$69.13 million [4]

Hecla Mining Company is set to release its quarterly earnings with an expected EPS of $0.163 and revenue of approximately $400.75 million.The company anticipates a significant year-over-year increase in earnings and revenue, supported by a 5% boost in silver production.Despite challenges, Hecla has outperformed the S&P 500 and reduced its net leverage to 0.3x, although it has underperformed compared to industry peers.Hecla Mining Company (NYSE:HL) is set to release its quarterly earnings on February 17, 202 ...

🚨 TETHER EARNS $16.34M IN 24 HOUR REVENUEThe top three protocol revenue producers over the last 24 hours:1) @tether - $16.34M2) @circle - $6.37M3) @HyperliquidX - $1.26M https://t.co/3QzYbPqzlU ...

Analysts predict a 22.4% decline in EPS to $0.52 for Q4 2025, despite a projected 2% revenue increase to $3.24 billion.Stability in EPS estimates over the past 30 days highlights analyst confidence, potentially impacting short-term stock performance.Financial metrics reveal a P/E ratio of 21.85 and a debt-to-equity ratio of 2.15, indicating market favorability but significant leverage.FirstEnergy Corporation (NYSE:FE) is set to release its fourth-quarter 2025 earnings on February 17, 2026. Analysts predict ...

Math: double the fee, double the revenue.Human: double the fee, half the revenue.Half the fee, double the revenue. 🤯Ben Kaufman (@_benkaufman):https://t.co/y8d47PG1nd ...

🚨 OINBASE CONFIRMS BASE SEQUENCER FEES HIT $19M IN Q4 ON LATEST EARNINGS CALLCFO Alesia Haas clarified on @coinbase's Q4 2025 earnings call that Base sequencer fees are recorded under "other transaction revenue," separate from subscription and services revenue.Gross sequencer revenue came in at approximately $19M for the quarter, with net revenue estimated at $15M after Ethereum L1 data costs and the Optimism Collective revenue share, according to Coin Metrics on chain analysis.For comparison, Base generate ...

pendle at $1.13 trading at 4x annual revenue with new tokenomics launching feb 14. 80% of protocol revenue now goes to token buybacks distributed to sPENDLE holders. arthur hayes sold at $1.34 after the 54% dump from december. $45m fees in 2025 on infrastructure that peaked at $13.4b tvl. the mechanics changed but the price hasn't caught up yet. ...

Core Insights - Applied Materials (AMAT) reported revenue of $7.01 billion for the quarter ended January 2026, reflecting a year-over-year decline of 2.2% and matching the EPS of $2.38 from the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $6.89 billion by 1.79%, while the EPS surpassed the consensus estimate of $2.19 by 8.53% [1] Financial Performance - The company’s shares have returned +12.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3] Geographic Net Sales - United States: $656 million, -28.5% year-over-year, below the estimate of $684.78 million [4] - Europe: $221 million, -33% year-over-year, below the estimate of $256.38 million [4] - Japan: $525 million, -2.8% year-over-year, slightly above the estimate of $518.68 million [4] - China: $2.1 billion, -6.6% year-over-year, above the estimate of $1.97 billion [4] - Taiwan: $1.72 billion, +45.6% year-over-year, below the estimate of $1.81 billion [4] - Southeast Asia: $335 million, +17.1% year-over-year, above the estimate of $271.34 million [4] - Korea: $1.46 billion, -12.5% year-over-year, above the estimate of $1.41 billion [4] Revenue Breakdown - Applied Global Services: $1.56 billion, matching the average estimate, -2.2% year-over-year [4] - Semiconductor Systems: $5.14 billion, above the average estimate of $4.97 billion, -4% year-over-year [4] - Corporate and Other: $312 million, above the estimate of $305.24 million, +845.5% year-over-year [4] Operating Income - Applied Global Services: $438 million, above the average estimate of $427.87 million [4] - Semiconductor Systems: $1.43 billion, below the average estimate of $1.81 billion [4]

DraftKings forecasts $6.9 billion revenue guidance on 'expected investment in DraftKings Predictions' https://t.co/nqYBcav0Mt ...